Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Noninterventional Study Evaluating Parkinson's Disease Diary Use
NCT05363046 · View on ClinicalTrials.gov ↗
Study Summary
This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
Conditions Studied
Study Locations (20)
New York
- Mount Sinai West — New York
- Weill Cornell Medicine - New York Presbyterian Hospital — New York
- University of Rochester Medical Center — Rochester
California
- David Geffen School of Medicine University of California Los Angeles — Los Angeles
- University of California, Irvine — Orange
Florida
- Movement Disorders Center of Boca Raton — Boca Raton
- University of Miami Health System — Miami
Bavaria
- Klinikum der Universität München - Campus Grosshadern — Munich
- Technischen Universitaet Muenchen (TUM) — Munich
Arizona
- Mayo Clinic Neurology — Scottsdale
Colorado
- University of Colorado — Aurora
Illinois
- Parkinson's Disease and Movement Disorders Center at Northwestern University Feinberg School of Medicine — Chicago
Kansas
- University of Kansas Medical Center — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363046
The ClinicalTrials.gov registry entry for NCT05363046 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BlueRock Therapeutics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05363046 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05363046 about?
NCT05363046 is a clinical study titled "Noninterventional Study Evaluating Parkinson's Disease Diary Use". This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
What is the current status of trial NCT05363046?
This trial is currently active not recruiting. The enrollment target is 194 participants. The study started on 2022-07-29. Estimated completion is 2026-10.
What conditions does trial NCT05363046 study?
This clinical trial studies the following conditions: Parkinson's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT05363046?
This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05363046 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.